Peregrine Capital Management’s Collegium Pharmaceutical COLL Stock Holding History

Peregrine Capital Management’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.68M	Buy	129,416 +33,110	+34%	+$1.13M	0.15%	215
2026 Q1	$3.18M	Buy	+96,306	New	+$4.08M	0.12%	238
2024 Q1	–	Sell	-344,532	Closed	-$10.6M	–	324
2023 Q4	$10.6M	Sell	344,532 -114,658	-25%	-$2.87M	0.32%	64
2023 Q3	$10.3M	Sell	459,190 -19,636	-4%	-$448K	0.31%	92
2023 Q2	$10.3M	Sell	478,826 -19,822	-4%	-$450K	0.28%	118
2023 Q1	$12M	Sell	498,648 -42,744	-8%	-$1.13M	0.35%	81
2022 Q4	$12.6M	Sell	541,392 -5,889	-1%	-$119K	0.39%	65
2022 Q3	$8.77M	Sell	547,281 -1,477	-0.3%	-$26K	0.28%	158
2022 Q2	$9.72M	Sell	548,758 -7,900	-1%	-$133K	0.29%	143
2022 Q1	$11.3M	Sell	556,658 -19,241	-3%	-$364K	0.27%	146
2021 Q4	$10.8M	Sell	575,899 -106,165	-16%	-$2.07M	0.22%	182
2021 Q3	$13.5M	Buy	+682,064	New	+$14.7M	0.28%	130

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Peregrine Capital Management's COLL Position: Q2 2026 in Review

Peregrine Capital Management increased its Collegium Pharmaceutical (COLL) stake by 34% in Q2 2026, buying an estimated $1.13M and bringing the position to 129,416 shares worth $4.68M. The position accounts for 0.15% of the portfolio, ranked #215.

Peregrine Capital Management first reported a position in COLL in Q3 2021 and has held it in 12 quarters since. The position peaked at $13.5M in Q3 2021. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Peregrine Capital Management held 129,416 shares of Collegium Pharmaceutical worth $4.68M as of Q2 2026.
Peregrine Capital Management bought 33,110 Collegium Pharmaceutical shares in Q2 2026, an estimated $1.13M.
Collegium Pharmaceutical made up 0.15% of Peregrine Capital Management's portfolio in Q2 2026, its #215 holding.
Peregrine Capital Management first reported a position in Collegium Pharmaceutical in Q3 2021 and has held it in 12 quarters since.
Peregrine Capital Management's Collegium Pharmaceutical position peaked at $13.5M in Q3 2021.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.